KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

被引：205

作者：

Ambrogio, Chiara ^{[1
]}

Kohler, Jens ^{[1
]}

Zhou, Zhi-Wei ^{[2
,3
]}

Wang, Haiyun ^{[4
]}

Paranal, Raymond ^{[1
]}

Li, Jiaqi ^{[1
]}

Capelletti, Marzia ^{[1
]}

Caffarra, Cristina ^{[1
]}

Li, Shuai ^{[1
]}

Lv, Qi ^{[4
]}

Gondi, Sudershan ^{[2
,3
]}

Hunter, John C. ^{[2
,3
]}

Lu, Jia ^{[2
,3
]}

Chiarle, Roberto ^{[5
,6
,7
]}

Santamaria, David ^{[8
]}

Westover, Kenneth D. ^{[2
,3
]}

Janne, Pasi A. ^{[1
,9
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA

[4] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China

[5] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA

[6] Harvard Med Sch, Boston, MA 02115 USA

[7] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy

[8] Univ Bordeaux, INSERM, U1218, ACT Lab,IECB, F-33600 Pessac, France

[9] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02215 USA

来源：

CELL | 2018年 / 172卷 / 04期

基金：

中国国家自然科学基金;

关键词：

CELL LUNG-CANCER; RAS FORMS DIMERS; WILD-TYPE RAS; THERAPEUTIC STRATEGY; PROLIFERATION; DOCETAXEL; PROTEINS; SURVIVAL; SITE;

D O I：

10.1016/j.cell.2017.12.020

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and underlies resistance to MEK inhibition. These effects are abrogated when wild-type KRAS is replaced by KRAS(D154Q), a mutant that disrupts dimerization at the alpha 4-alpha 5 KRAS dimer interface without changing other fundamental biochemical properties of KRAS, both in vitro and in vivo. Moreover, dimerization has a critical role in the oncogenic activity of mutant KRAS. Our studies provide mechanistic and biological insights into the role of KRAS dimerization and highlight a role for disruption of dimerization as a therapeutic strategy for KRAS mutant cancers.

引用

页码：857 / +

页数：27

共 50 条

[41] Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors [J].

Adashek, Jacob J. ;

Menta, Arjun K. ;

Reddy, Neha K. ;

Desai, Aakash P. ;

Roszik, Jason ;

Subbiah, Vivek .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (06) :871-878

[42] Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12) [J].

Liu, Ye ;

Li, Yan ;

Li, Guohui ;

Wang, Anhui ;

Chu, Huiying .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2024, 760

[43] Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy [J].

Zhao, Qingci ;

Haga, Ryoka ;

Tamura, Satoko ;

Shimada, Ichio ;

Nishida, Noritaka .

SCIENTIFIC REPORTS, 2023, 13 (01)

[44] Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway [J].

Chu, Po-Chen ;

Lin, Peng-Chan ;

Wu, Hsing-Yu ;

Lin, Kuen-Tyng ;

Wu, Christina ;

Bekaii-Saab, Tanios ;

Lin, Yih-Jyh ;

Lee, Chung-Ta ;

Lee, Jeng-Chang ;

Chen, Ching-Shih .

ONCOGENE, 2018, 37 (25) :3440-3455

[45] Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network [J].

Roman, Marta ;

Lopez, Ines ;

Guruceaga, Elisabeth ;

Baraibar, Iosune ;

Ecay, Margarita ;

Collantes, Maria ;

Nadal, Ernest ;

Vallejo, Adrian ;

Cadenas, Silvia ;

Echavarri-de Miguel, Marta ;

Jang, Jae Hwi ;

San Martin-Uriz, Patxi ;

Castro-Labrador, Laura ;

Vilas-Zornoza, Amaia ;

Lara-Astiaso, David ;

Ponz-Sarvise, Mariano ;

Rolfo, Christian ;

Santos, Edgardo S. ;

Raez, Luis E. ;

Taverna, Simona ;

Behrens, Carmen ;

Weder, Walter ;

Wistuba, Ignacio I. ;

Vicent, Silvestre ;

Gil-Bazo, Ignacio .

CANCER RESEARCH, 2019, 79 (03) :625-638

[46] Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer [J].

Yoon, Shinkyo ;

Yang, Hannah ;

Ryu, Hyun-Min ;

Lee, Eunjin ;

Jo, Yujin ;

Seo, Seyoung ;

Kim, Deokhoon ;

Lee, Chang Hoon ;

Kim, Wanlim ;

Jung, Kyung Hae ;

Park, Sook Ryun ;

Choi, Eun Kyung ;

Kim, Sang-We ;

Park, Kang-Seo ;

Lee, Dae Ho .

CANCER RESEARCH AND TREATMENT, 2022, 54 (03) :767-781

[47] Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network [J].

Chatterjee, Suman ;

Huang, Eric H. -B. ;

Christie, Ian ;

Kurland, Brenda F. ;

Burns, Timothy F. .

MOLECULAR CANCER THERAPEUTICS, 2017, 16 (05) :793-804

[48] Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer [J].

von Itzstein, Mitchell S. ;

Burns, Timothy F. ;

Dowell, Jonathan E. ;

Horn, Leora ;

Camidge, D. Ross ;

York, Sally J. ;

Eaton, Keith D. ;

Kyle, Kelly ;

Fattah, Farjana ;

Liu, Jialiang ;

Mu-Mosley, Hong ;

Gupta, Arjun ;

Nadeem, Urooba ;

Gao, Ang ;

Zhang, Song ;

Gerber, David E. .

CLINICAL CANCER RESEARCH, 2025, 31 (04) :639-648

[49] Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer [J].

van Geel, Robin M. J. M. ;

van Brummelen, Emilie M. J. ;

Eskens, Ferry A. L. M. ;

Huijberts, Sanne C. F. A. ;

de Vos, Filip Y. F. L. ;

Lolkema, Martijn P. J. K. ;

Devriese, Lot A. ;

Opdam, Frans L. ;

Marchetti, Serena ;

Steeghs, Neeltje ;

Monkhorst, Kim ;

Thijssen, Bas ;

Rosing, Hilde ;

Huitema, Alwin D. R. ;

Beijnen, Jos H. ;

Bernards, Rene ;

Schellens, Jan H. M. .

BRITISH JOURNAL OF CANCER, 2020, 122 (08) :1166-1174

[50] Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR [J].

Belmont, Peter J. ;

Jiang, Ping ;

Mckee, Trevor D. ;

Xie, Tao ;

Isaacson, Jason ;

Baryla, Nicole E. ;

Roper, Jatin ;

Sinnamon, Mark J. ;

Lee, Nathan V. ;

Kan, Julie L. C. ;

Guicherit, Oivin ;

Wouters, Bradly G. ;

O'Brien, Catherine A. ;

Shields, David ;

Olson, Peter ;

VanArsdale, Todd ;

Weinrich, Scott L. ;

Rejto, Paul ;

Christensen, James G. ;

Fantin, Valeria R. ;

Hung, Kenneth E. ;

Martin, Eric S. .

SCIENCE SIGNALING, 2014, 7 (351)

← 1 2 3 4 5 →